Core Viewpoint - Yifang Biopharma has submitted an application for H-share listing on the Hong Kong Stock Exchange, focusing on innovative targeted drugs for major diseases such as cancer and autoimmune diseases [1] Group 1: Company Overview - Yifang Biopharma specializes in the development of innovative targeted drugs, with a product pipeline that includes two marketed products and several candidates in various stages of clinical development [1] - The company's marketed products, Bafetinib and Gsorese, are included in the National Medical Insurance Drug List in China, generating revenue through external licensing [1][2] - As of the first nine months of 2025, the company reported revenue of 30.89 million yuan and a net loss attributable to shareholders of 181 million yuan, with R&D expenses amounting to 190 million yuan [1] Group 2: R&D Focus and Market Potential - Yifang Biopharma is heavily investing in R&D, particularly in new drugs such as D-2570 for psoriasis and D-0502 for breast cancer, while still in the "burning cash" phase [2] - The number of psoriasis patients in China is projected to reach 6.1 million by 2035, with the global psoriasis drug market expected to grow from $23.9 billion in 2024 to $47 billion by 2035 [2] - The company plans to initiate additional clinical trials for D-2570 targeting PsA, SLE, and vitiligo, indicating a broadening of its therapeutic focus [2] Group 3: Pricing and Market Competition - Bafetinib was included in the National Medical Insurance Directory in 2023, leading to a significant price reduction from approximately 6,000 yuan to about 2,800-2,862 yuan per box, a decrease of 52%-53% [3] - The inclusion of innovative drugs in the National Medical Insurance Directory typically results in increased market competition and reduced profit expectations for pharmaceutical companies [3] - Yifang Biopharma faces challenges with its marketed products due to price pressures and intense competition, while over half of the funds raised from its A-share IPO have already been consumed [3][4] Group 4: Financial Performance - Yifang Biopharma's IPO in July 2022 raised approximately 2.084 billion yuan, with a share price of 18.12 yuan [4] - The company has reported cumulative net losses exceeding 1.189 billion yuan from 2022 to September 2025, indicating ongoing financial challenges [4]

Group 1 - Company has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor [1] - Company is a research-driven biopharmaceutical firm based in China, focusing on significant unmet medical needs in oncology, autoimmune diseases, and metabolic diseases [1] - As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products, two core products in clinical stages, one candidate in clinical stage, and three candidates in preclinical stage [1] Group 2 - The commercialized products include BPI-D0316, a third-generation EGFR tyrosine kinase inhibitor for EGFR mutation-positive non-small cell lung cancer (NSCLC), which has been approved and included in the National Medical Insurance Drug List in China [1] - Another commercialized product, D-1553, is a KRAS G12C inhibitor, the first self-developed product in this target area to enter clinical stages in China, also approved and included in the National Medical Insurance Drug List [1] - The company has signed an agreement with Zhengda Tianqing to grant exclusive rights for the development, registration, production, and commercialization of D-1553 in mainland China [1] Group 3 - The core clinical-stage product D-2570 is undergoing a registrational Phase III clinical trial for plaque psoriasis and ulcerative colitis (UC), with plans to initiate additional trials for psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), and vitiligo [2] - Tairisig is an oral selective estrogen receptor degrader (SERD) currently in a registrational Phase III clinical trial for ER+/HER2- breast cancer [2] - The global and Chinese markets for oncology drugs, targeted oncology drugs, psoriasis drugs, UC drugs, and SERD drugs show significant growth potential, with the Chinese targeted oncology drug market expected to reach $61.6 billion by 2035 [2]